12 Recent Developments in Cell and Gene Therapy as of April 22, 2022

There have been a number of recent developments in cell and gene therapy, as detailed in our bimonthly newsletter, Cell and Gene Therapy Business Outlook. In public offering news, Massachusetts-based Selecta Biosciences has announced a $38.7 million public offering to continue developing ImmTOR, its antigen-specific immune tolerance platform. Leading the private financing news, Cambridge-based cell […]

13 Recent Developments in Cell and Gene Therapy as of April 8, 2022

There have been a number of recent developments in cell and gene therapy, as detailed in our bimonthly newsletter, Cell and Gene Therapy Business Outlook. Bristol Myers Squibb, based in New York, NY, has announced that the European Commission (EC) has granted Marketing Authorization for Breyanzi (lisocabtagene maraleucel; liso-cel), its CD19-targeted chimeric antigen receptor (CAR)-T […]

14 Recent Developments in Cell and Gene Therapy as of March 22, 2022

There have been a number of recent developments in cell and gene therapy, as detailed in our bimonthly newsletter, Cell and Gene Therapy Business Outlook. EdiGene, a gene-editing company based in Beijing, China, has entered a non-exclusive, worldwide license agreement with Boston Children’s Hospital (BCH) for intellectual property rights covering the upregulation of fetal hemoglobin […]

VIDEO: 5 Key Trends in Cell and Gene Therapy

Learn about these 5 key trends based on research featured in Cell Therapy and Gene Therapy Markets, 2021-2031 (published Feb. 2022), a recent report by Kalorama Information Cell and gene therapy products are transforming the treatment of many acquired diseases such as cancer, diabetes, Parkinson’s disease and genetic diseases to correct defective genetic material. Additionally, […]

11 Recent Developments in Cell and Gene Therapy as of March 2022

There have been a number of recent developments in cell and gene therapy, as detailed in our bimonthly newsletter, Cell and Gene Therapy Business Outlook. The US Patent and Trademark Office has ruled against a patent challenge by the University of California, Berkeley (UC Berkeley) over patents awarded to the Broad Institute of MIT and […]

Tenfold Growth for $5.2 Billion Cell and Gene Therapy Market from 2021-2031

“Oncology, cardiovascular-blood and genetic conditions will be key contributors to the cell and gene therapy market’s strong performance through 2031.” – Kalorama Information   It is an exciting and interesting time for companies involved in cell and gene therapy as the industry is forecast to grow tenfold between 2021 to 2031, according to leading medical […]

10 Recent Developments in Cell and Gene Therapy

There have been a number of recent developments in cell and gene therapy, as detailed in our bimonthly newsletter, Cell and Gene Therapy Business Outlook. Intellia Therapeutics, based in Cambridge, MA, has acquired Berkeley, CA-based Rewrite Therapeutics, a private biotech company specializing in developing novel genome editing technologies. Rewrite’s Rewriter platform utilizes CRISPR-guided DNA polymerases […]

This Week in Cell and Gene Therapy: 12 Recent Developments

The following are a dozen developments in the cell and gene therapy market from Volume 1, Issue 14 of Cell and Gene Therapy Business Outlook, published January 10, 2022.   Allogene Therapeutics, based South San Francisco, CA, has announced that the Food and Drug Administration has cleared the company to resume clinical trials its CAR-T […]

19 Need-To-Know Developments in Cell and Gene Therapy

The following are recent developments in Cell and Gene Therapy, from Volume 1, Issue 13 of Cell and Gene Therapy Business Outlook, published December 22, 2021 Arrowhead Pharmaceuticals, based in Pasadena, CA, has completed a purchase of 13 acres in the Verona Technology Park in Verona, WI, where it plans to invest between $200 million […]

$54.4 Billion in Deals and Counting: Analyzing Three Quarters of Cell and Gene Therapy Funding

Over 54 BN across funding mechanisms.  Private, VC, SPAC and and IPO Over 20Billion The enormous amount of funding presages confidence in discoveries of future marketable products as well as platforms in cell and gene therapy.  With an aggressive third quarter 2021 for funding, it is worthwhile to total and assess where we are.  In […]